

SPECIAL ARTICLE

Cornelia de Lange Spectrum



Ángela Ascaso^a, María Arnedo^b, Beatriz Puisac^b, Ana Latorre-Pellicer^b, Julia del Rincón^c, Gloria Bueno-Lozano^c, Juan Pié^b, Feliciano J. Ramos^{c,*}

^a Consulta de Pediatría, Centro de Salud Delicias Sur, Zaragoza, Spain

^b Laboratorio de Genética Clínica y Genómica Funcional, Facultad de Medicina, Universidad de Zaragoza, Zaragoza, Spain

^c Unidad de Genética Clínica, Servicio de Pediatría, Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain

Received 27 December 2023; accepted 11 March 2024

Available online 11 May 2024

KEYWORDS

CdLS;
Cornelia de Lange syndrome;
Cohesin;
NIPBL;
HDAC8;
SMC1A;
RAD21;
SMC3;
Cornelia de Lange spectrum;
CdLSp

Abstract Cornelia de Lange syndrome (CdLS) is a rare congenital developmental disorder with multisystemic involvement. The clinical presentation is highly variable, but the classic phenotype, characterized by distinctive craniofacial features, pre- and postnatal growth retardation, extremity reduction defects, hirsutism and intellectual disability can be distinguished from the nonclassic phenotype, which is generally milder and more difficult to diagnose. In addition, the clinical features overlap with those of other neurodevelopmental disorders, so the use of consensus clinical criteria and artificial intelligence tools may be helpful in confirming the diagnosis.

Pathogenic variants in *NIPBL*, which encodes a protein related to the cohesin complex, have been identified in more than 60% of patients, and pathogenic variants in other genes related to this complex in another 15%: *SMC1A*, *SMC3*, *RAD21*, and *HDAC8*. Technical advances in large-scale sequencing have allowed the description of additional genes (*BRD4*, *ANKRD11*, *MAU2*), but the lack of molecular diagnosis in 15% of individuals and the substantial clinical heterogeneity of the syndrome suggest that other genes and mechanisms may be involved.

Although there is no curative treatment, there are symptomatic/palliative treatments that paediatricians should be aware of. The main medical complication in classic CdL is gastroesophageal reflux (GER), which should be treated early.

© 2024 Asociación Española de Pediatría. Published by Elsevier España, S.L.U. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

DOI of original article: <https://doi.org/10.1016/j.anpede.2024.03.002>

* Corresponding author.

E-mail address: framoss@unizar.es (F.J. Ramos).

PALABRAS CLAVE

SCdL;
Síndrome Cornelia de Lange;
Cohesina;
NIPBL;
HDAC8;
SMC1A;
RAD21;
SMC3;
Espectro Cornelia de Lange;
ECdL

Espectro Cornelia de Lange

Resumen El síndrome de Cornelia de Lange (SCdL) es un raro trastorno congénito del desarrollo de afectación multisistémica. Las manifestaciones clínicas son muy variables, pero se distingue entre un fenotipo clásico, caracterizado por unos rasgos craneofaciales distintivos, retraso del crecimiento pre y postnatal, defectos por reducción de las extremidades, hirsutismo y discapacidad intelectual y un fenotipo no clásico, generalmente más leve y más difícil de diagnosticar. Además, las características clínicas se superponen con las de otros desordenes del neurodesarrollo, por lo que la utilización de criterios clínicos consensuados y herramientas de inteligencia artificial pueden ser útiles para confirmar el diagnóstico.

En más del 60% de los pacientes se han identificado variantes patogénicas en el gen *NIPBL*, que codifica una proteína relacionada con el complejo de la cohesina, y en otro 15% en 4 genes también asociados a este complejo: *SMC1A*, *SMC3*, *RAD21* y *HDAC8*. Los progresos técnicos en las técnicas de secuenciación masiva han permitido describir otros genes relacionados (*BRD4*, *ANKRD11* y *MAU2*), pero la ausencia de diagnóstico molecular en el 15% de los casos y la gran heterogeneidad clínica del síndrome, sugiere la existencia de otros genes y mecanismos relacionados.

Aunque no haya un tratamiento curativo, sí hay tratamientos sintomáticos/paliativos que deben ser conocidos por el pediatra. La principal complicación médica en el SCdL clásico es el reflujo gastroesofágico (RGE), que debe ser tratado de forma precoz y contundente, ya que es una de las causas más frecuentes de fallecimiento en estos pacientes.

© 2024 Asociación Española de Pediatría. Publicado por Elsevier España, S.L.U. Este es un artículo Open Access bajo la licencia CC BY-NC-ND (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

Introduction

Cornelia de Lange syndrome (CdLS) is a rare disease named after the Dutch paediatrician Cornelia de Lange, who in 1933 published the cases of two unrelated female infants who presented with very similar phenotypes.¹ She called the syndrome *typus degenerativus amstelodamensis*, in honour of the city of Amsterdam where she worked. Before that, in 1916, Brachmann had published the case of a patient with growth retardation, hirsutism and bilateral monodactyly that has since been recognised as the first documented case of CdLS,² which is why some publications refer to this disease as Brachmann-de Lange syndrome.

At present, the prevalence of CdLS is estimated at 1 case per 10 000 – 30 000 live birth births in the general population.³ This includes cases with atypical presentations of CdLS that were not diagnosed in previous decades when the genetic tests currently used were not yet available.

Clinical forms**Classic Cornelia de Lange syndrome**

Classic CdLS, recognisable at birth, has a characteristic phenotype consisting of distinctive craniofacial features, intrauterine and postnatal growth retardation, reduction deformities (especially the upper extremities), hirsutism and psychomotor delay/intellectual disability. Additional abnormalities in more than one system are also common: gastro-oesophageal reflux (the most frequent and important medical complication in patients with CdLS), sensorineural

hearing loss, congenital heart disease and renal and genital anomalies, among others.^{3,4}

The *distinctive craniofacial features* include microcephaly with brachycephaly, synophrys, thick arched eyebrows, long eyelashes, short nose with a concave nasal ridge and anteverted nares, a long philtrum and thin upper lip and retrognathia^{3,4} (Fig. 1 and Table 1).

Growth retardation is very frequent and starts antenatally. Patients exhibit generalised and symmetrical microsomia that results in low weight, short stature and microcephaly persisting through adulthood.^{5,6} This has prompted the development of specific growth charts for this syndrome.⁷ Although growth hormone levels are usually normal, some patients with low levels have been managed with growth hormone replacement therapy.^{8,9}

Psychomotor delay and/or intellectual disability are present in most patients with classic CdLS and are usually severe.¹⁰ They are usually associated with absent or delayed expressive language development and autism spectrum and other behavioural disorders. From a neurologic standpoint, affected patients may have epilepsy, motor disorders (stereotypical movements) and abnormalities in sensory processing (hypoalgesia or heat or cold intolerance), hypotonia or sleep disturbances. Recently, evidence has emerged of autonomic nervous system involvement with small fibre neuropathy, in some cases associated with asymmetries in the sympathetic responses in the lower extremities.¹¹

Limb abnormalities are present in 80% of cases. Between 25% and 30% of patients have severe malformations, chiefly reduction deformities in the upper extremities, such as monodactyly or oligodactyly, while the rest usually have small



Face	Extremities	Face2Gene	Clinical score	Involved gene
		 Image Comparison CASE PHOTO ✓ COMPOSITE PHOTO ✓ Similarity HIGH MED LOW GESTALT FEATURE	15	<i>NIPBL</i>
		 Image Comparison CASE PHOTO ✓ COMPOSITE PHOTO ✓ Similarity HIGH MED LOW GESTALT FEATURE	13	<i>HDAC8</i>
		 Image Comparison CASE PHOTO ✓ COMPOSITE PHOTO ✓ Similarity HIGH MED LOW GESTALT FEATURE	11	<i>SMC1A</i>
		 Image Comparison CASE PHOTO ✓ COMPOSITE PHOTO ✓ Similarity HIGH MED LOW GESTALT FEATURE	10	<i>HDAC8</i>
		 Image Comparison CASE PHOTO ✓ COMPOSITE PHOTO ✓ Similarity HIGH MED LOW GESTALT FEATURE	9	<i>NIPBL</i>

Figure 1 Facial features and limb abnormalities in patients with CdLS and pathogenic variants in different causative genes. The figure also shows the analysis made with the Face2Gene software and the scores calculated using the criteria proposed by Kline et al.³

hands or feet that may be associated with minor malformations, such as proximally placed thumbs or clinodactyly. These anomalies are usually bilateral and asymmetrical (Fig. 1, Table 1).

Gastro-esophageal reflux (GER) is the main medical disorder in classic CdLS, affecting 93.3% of patients.^{13,14} Patients must be assessed for GOR from an early age, especially if they exhibit feeding problems, by means of oesophageal pH impedance or manometry or, if not available, a barium swallow. When not managed appropriately (see the "Treatment and Follow-up" section below), GOR can cause complications such as oesophagitis, pneumonitis/aspiration pneumonia and behavioural changes (irritability, self-injury, etc.) that are frequently treated inappropriately with psychotropic drugs.

Other possible gastrointestinal abnormalities, which are much less frequent, include intestinal malrotation (2%–3% of cases), which must always be considered in patients with CdLS presenting in the emergency department with acute abdominal pain, pyloric stenosis (7%) or congenital diaphragmatic hernia.¹⁵

In the sensory area, the most frequent complication is *sensorineural hearing loss*, found in 80% of patients, of who nearly half have severe bilateral hearing loss.¹⁶ When it comes to vision, palpebral ptosis, usually bilateral, and myopia (>50% cases) are frequent, as is nystagmus (40%). Less frequent ophthalmological features include dacryostenosis, strabismus, microcornea, glaucoma or optic nerve coloboma.¹⁷

As regards the cardiovascular system, approximately one third of patients have congenital heart anomalies, most frequently atrial or ventricular septal defect, pulmonary valve stenosis, tetralogy of Fallot, hypoplastic left heart syndrome and bicuspid aortic valve.¹⁸

A recent study demonstrated that some patients may develop early cardiomyopathy that can be detected through speckle-tracking echocardiography before the development of symptoms or other echocardiographic or laboratory abnormalities.¹⁹

In the genitourinary system, *cryptorchidism* is frequent in male patients (75%), bicornate uterus in female patients (25%) and hypoplasia of genitalia in patients of any sex (50%). Renal anomalies are rare, and the most frequent one is vesicoureteral reflux²⁰ (10%) (Table 1).

A degree of endocrine dysregulation has also been described, including abnormal levels of prolactin and delayed puberty. Abnormal results in the Homeostatic Model Assessment for Insulin Resistance (HOMA-IR) have been associated with early development of insulin resistance in some patients.⁹ Low-levels of lean mass and decreased bone density have also been reported.²¹

Other, less frequent identified abnormalities include cleft palate, dental anomalies, cutis marmorata and low-pitched cry.³

Natural history

In patients with classic CdLS, the diagnosis is usually made at birth and therefore appropriate treatment can be initiated early, especially as regards nutrition, which frequently requires placement of a nasogastric tube or even performance of gastrostomy to be maintained for

the first few months or even years of life. It is important to take into account that in these patients, anthropometric measurements at birth and during growth and development tend to be at percentiles below the normal range, and therefore paediatricians should not insist on overfeeding, which would only worsen the GOR experienced by most patients with CdLS. Therefore, we recommend using specific growth charts for this syndrome (available at <https://www.corneliadelange.es/>). The most frequent complications throughout the lifespan are pneumonia/pneumonitis due to aspiration of stomach acid (from GER), which is one of the leading causes of early mortality¹⁴ (31% of deaths), bowel obstruction (due to volvulus in cases of intestinal malrotation) (19%), complications from severe congenital anomalies (congenital diaphragmatic hernia or heart defects) (15%). Other causes of early mortality were neurologic complications, accidental injury (8%) and sepsis (4%).

Non-classic Cornelia de Lange syndrome

Beyond classic CdLS, advances in genetic diagnosis have allowed the diagnosis of additional non-classic CdLS phenotypes, usually milder, that may be difficult to identify for paediatricians. Due to the substantial phenotypic heterogeneity of these atypical forms, some authors prefer to use the term *Cornelia de Lange spectrum* instead of *syndrome*.

In general, patients with atypical forms tend to have a more nonspecific phenotype (less pronounced features) compared to patients with classic phenotypes, and the most salient features may be synophrys and the facial gestalt (Fig. 1).

Differential diagnosis

The differential diagnosis of CdLS can be complex due to the variability of its clinical manifestations and the overlap with other genetic neurodevelopmental disorders, such as Coffin-Siris syndrome, Rubinstein-Taybi syndrome, KBG syndrome, CHOPS syndrome or Wiedemann-Steiner syndrome.^{22–26} In 2018, a consensus group of international experts proposed clinical diagnostic criteria that paediatricians could apply easily when they encounter patients with suspected CdLS³ (Table 2). These criteria allow differentiation between classic and non-classic phenotypes and of CdLS and diseases with similar presentations. It is based on assigning a specific value to a series of cardinal features and other suggestive features and, based on the obtained score, classification as classic CdLS (score ≥ 11 points, with at least 3 cardinal features present) and non-classic CdLS (score of 9–10 points, with at least 2 cardinal features present). In addition, a score between 4 and 8 points warrants performance of molecular testing for CdLS to make the diagnosis (Table 2).

In addition, in recent years artificial intelligence (AI) tools have been developed that facilitate the clinical diagnosis of rare diseases through the analysis of facial morphology. Latorre et al.²⁷ tested the Face2Gene application (<https://www.face2gene.com>) using frontal facial photographs of individuals with CdLS. Their results showed that the software offered a high sensitivity in the facial

Table 1 Clinical manifestations of CdLS organised by category, defined features, HPO (Human Phenotype Ontology) ID and frequency.

Category	HPO ID	HPO name	Frequency	Category	HPO ID	HPO name	Frequency
Growth	HP:0004322	Short stature	Very frequent	Skeletal system	HP:0000248	Brachycephaly	Very frequent
	HP:0001508	Failure to thrive	Frequent		HP:0000347	Micrognathia	Very frequent
	HP:0001511	Intrauterine growth retardation	Frequent		HP:0000470	Short neck	Very frequent
	HP:0008850	Severe postnatal growth retardation	Frequent		HP:0001770	Toe syndactyly 2-3	Very frequent
	HP:0001956	Truncal obesity	Occasional		HP:0001773	Short foot	Very frequent
Head and neck	HP:0000218	High palate	Very frequent		HP:0002750	Delayed skeletal maturation	Very frequent
	HP:0000233	Thin vermillion border	Very frequent		HP:0002983	Micromelia	Very frequent
	HP:0000343	Long philtrum	Very frequent		HP:0009623	Proximal placement of thumb	Very frequent
	HP:0000463	Anteverted nares	Very frequent		HP:0010034	Short 1st metacarpal	Very frequent
	HP:0000684	Delayed eruption of teeth	Very frequent		HP:0200055	Small hand	Very frequent
	HP:0000687	Widely spaced teeth	Very frequent		HP:0001387	Joint stiffness	Frequent
	HP:0002714	Downturned corners of mouth	Very frequent		HP:0002974	Radioulnar synostosis	Frequent
	HP:0003196	Short nose	Very frequent		HP:0003042	Elbow dislocation	Frequent
	HP:0005280	Depressed nasal bridge	Very frequent		HP:0004209	Clinodactyly of the 5th finger	Frequent
	HP:0000498	Blepharitis	Frequent		HP:0000767	Pectus excavatum	Occasional
Auditory system	HP:0000175	Cleft palate	Occasional		HP:0001385	Hip dysplasia	Occasional
	HP:0000453	Choanal atresia	Occasional		HP:0002827	Hip dislocation	Occasional
	HP:0010880	Increased nuchal translucency	Occasional		HP:0040071	Abnormal morphology of ulna	Occasional
	HP:0000413	Atresia of the external auditory canal	Very frequent		HP:0012165	Oligodactyly	Occasional
	HP:0000368	Low-set, posteriorly rotated ears	Frequent	Muscular system	HP:0001276	Hypertonia	Very frequent
Visual system	HP:0000405	Conductive hearing impairment	Frequent		HP:0000776	Congenital diaphragmatic hernia	Occasional
	HP:0000407	Sensorineural hearing impairment	Frequent		HP:0001252	Hypotonia	Occasional
	HP:0000400	Macrotia	Occasional	Extremities	HP:0001883	Talipes	Occasional
	HP:0000482	Microcornea	Frequent		HP:0000294	Low anterior hairline	Very frequent

Table 1 (Continued)

Category	HPO ID	HPO name	Frequency	Category	HPO ID	HPO name	Frequency
Cardiovascular system	HP:0000508	Ptosis	Frequent	Nervous system	HP:0000527	Long eyelashes	Very frequent
	HP:0000545	Myopia	Frequent		HP:0000574	Thick eyebrow	Very frequent
	HP:0000667	Phthisis bulbi	Frequent		HP:0000664	Synophrys	Very frequent
	HP:0000486	Strabismus	Occasional		HP:0002162	Low posterior hairline	Very frequent
	HP:0000501	Glaucoma	Occasional		HP:0002230	Generalised hirsutism	Very frequent
	HP:0000518	Cataract	Occasional		HP:0002553	Highly arched eyebrow	Very frequent
	HP:0000639	Nystagmus	Occasional		HP:0007665	Curly eyelashes	Very frequent
	HP:0001629	Ventricular septal defect	Occasional		HP:0000965	Cutis marmorata	Frequent
	HP:0001631	Atrial septal defect	Occasional		HP:0007598	Bilateral single transverse palmar creases	Frequent
Breast	HP:0030680	Abnormal cardiovascular system morphology	Occasional	Nervous system	HP:0000252	Microcephaly	Very frequent
	HP:0002557	Hypoplastic nipples	Frequent		HP:0001249	Intellectual disability	Very frequent
	HP:0002020	Gastro-esophageal reflux	Very frequent		HP:0010300	Abnormally low-pitched voice	Very frequent
Gastrointestinal system	HP:0008872	Feeding difficulties in infancy	Frequent	Endocrine system	HP:0010864	Intellectual disability, severe	Very frequent
	HP:0002021	Pyloric stenosis	Occasional		HP:0000722	Compulsive behaviours	Frequent
	HP:0002566	Intestinal malrotation	Occasional		HP:0000739	Anxiety	Frequent
	HP:0002580	Volvulus	Occasional		HP:0002167	Abnormality of speech or vocalization	Frequent
	HP:0000823	Delayed puberty	Occasional		HP:0002360	Sleep abnormality	Frequent
Genitourinary system	HP:0000003	Multicystic kidney dysplasia	Frequent	Genitourinary system	HP:0007018	Attention-deficit hyperactivity disorder	Frequent
	HP:0000028	Cryptorchidism	Frequent		HP:0000717	Autism	Occasional
	HP:0000047	Hypospadias	Frequent		HP:0001250	Seizure	Occasional
	HP:0000059	Hypoplastic labia majora	Frequent		HP:0002119	Ventriculomegaly	Occasional
	HP:0000076	Vesicoureteral reflux	Frequent		HP:0002120	Cerebral cortical atrophy	Occasional
	HP:0008736	Hypoplasia of penis	Frequent	Prenatal development and birth	HP:0007360	Aplasia/hypoplasia of the cerebellum	Occasional
	HP:0000083	Renal insufficiency	Occasional		HP:0009830	Peripheral neuropathy	Occasional
	HP:0000130	Abnormality of the uterus	Occasional		HP:0001622	Premature birth	Frequent
	HP:0000786	Primary amenorrhoea	Occasional		HP:0001557	Prenatal movement abnormality	Occasional

Frequency categories in Human Phenotype Ontology (HPO, <https://hpo.jax.org/app/>) system: Very frequent 99–80%; Frequent 79–30%; Occasional 29–5%.

Table 2 Clinical features of Cornelia de Lange syndrome.


[0,1-2]Main features (2 points each)	
Synophrys and/or thick eyebrows	HP:0000664 and/or HP:0000574
Short nose, concave nasal ridge and/or upturned nasal tip	HP:0003196, HP:0011120 and/or HP:0000463
Long and/or smooth philtrum	HP:0000343 and/or HP:0000319
Thin upper lip vermillion and/or downturned corners of mouth	HP:0000219 and/or HP:0002714
Hand oligodactyly and/or adactyly	HP:0001180 and/or HP:0009776
Congenital diaphragmatic hernia	HP:0000776
[0,1-2]Suggestive features (1 point each)	
Global developmental delay and/or intellectual disability	HP:0001263 and/or HP:0001249
Prenatal growth retardation	HP:0001511
Postnatal growth retardation	HP:0008897
Microcephaly (prenatally and/or postnatally)	HP:0000252
Small hands and/or feet	HP:0200055 and/or HP:0001773
Short 5th finger	HP:0009237
Hirsutism	HP:0001007

Interpretation of score: ≥ 11 points, of which at least 3 are main classic CdLS.

9 or 10 points, of which at least 2 are main: non-classic CdLS.

4–8 points, of which at least 1 is main molecular testing for CdLS indicated.

<4 points: insufficient to indicate molecular testing for CdLS.

**Figure 2** Algorithm for the clinical diagnosis of CdLS.

recognition of CdLS, with a success rate of 83.7% defining success as CdLS being the disorder listed as the first prediction (Fig. 1).

In short, at the time of diagnosis (Fig. 2) it is key to take a thorough history with a standardized history-taking approach, collecting clinical information using Human Phenotype Ontology (HPO) codes (Table 1). In addition, AI tools for facial phenotyping may become increasingly useful (Fig. 1). However, the definitive clinical diagnosis, and the classification as classic or non-classic CdLS should be based on the criteria defined by Kline et al.³ (Table 2).

Molecular diagnosis

Cornelia de Lange syndrome can be diagnosed by the identification of a pathogenic variant in one of the 5 causative genes associated with the cohesin complex (*NIPBL*, *SMC1A*, *SMC3*, *RAD21*, *HDAC8*) and, with less certainty, in 3 recently described additional genes (*BRD4*, *ANKRD11*, *MAU2*).^{28,29} The

cohesin complex consists of a central ring formed by proteins *SMC1A*, *SMC3* and *RAD21* and a series of regulatory proteins such as *NIPBL*, the main protein involved in loading cohesins on DNA, and *HDAC8*, a *SMC3* deacetylase that allows the release of the cohesin complex from chromatin³ (Fig. 3).

The cohesin complex is a multifunctional complex involved in many biological processes, such as chromosome segregation, genomic stabilization and organization and, above all, regulation of gene expression. Most individuals with CdLS (more than 60%) have a pathogenic variant of *NIPBL*, a gene that encodes a protein that interacts with chromatin remodelers and transcription factors.³⁰ This is the reason that CdLS is classified as a transcriptopathology, that is, a disease caused by the global dysregulation of gene expression throughout the organism, which explains the multisystemic involvement and the phenotypic variability of this syndrome.²⁸

Technological advances in high-throughput sequencing in recent years have allowed the identification of new causative genes, especially in patients with non-classic phenotypes. Among the salient ones are *ANKRD11*, which encodes a protein involved in transcriptional regulation,²⁴ or *MAU2* and *BDR4*, which encode proteins that interact with *NIPBL*^{29,31} (Fig. 3).

This substantial clinical and genetic heterogeneity, especially in individuals with non-classic/mild or atypical CdLS, can pose a barrier to molecular diagnosis. Therefore, the use of next-generation sequencing techniques allowing simultaneous evaluation of a large number of genes is recommended for the initial approach to genetic diagnosis (Fig. 4). In recent years, the general approach has been to use of panels that include genes known to cause CdLS and other genes associated with neurodevelopmental disorders, or clinical exome sequencing to simultaneously evaluate up to 7000




Figure 3 Location of the proteins that cause Cornelia de Lange syndrome: NIPBL and BRD4 are responsible for nucleosome clearance in DNA so that proteins SMC1A, SMC3, RAD21 and STAG2 can form the cohesin ring. MAU2 forms a heterodimeric complex with NIPBL to help load cohesin on chromatin. Then, protein HDAC8 deacetylates SMC3, allowing the release of the cohesin ring. Protein ANKRD11 is involved in the transcription activation process.

genes associated with disease. On the other hand, given the improvement of molecular technologies, the reduction in the costs of sequencing and the automation of data analysis, it is possible that in upcoming years whole-exome or even whole-genome sequencing will replace these techniques.

If all these techniques yield negative results, performance of array comparative genomic hybridization (CGH) is recommended to assess for chromosomal anomalies or copy number variants.

The presence of somatic mosaicism in some individuals (10%–13%) may pose an additional difficulty and require analysis in specialised laboratories of other tissues, such as oral mucosa specimens or fibroblasts, and the use of highly sensitive molecular diagnostic techniques when results in blood samples turn out negative.^{32,33}

If this still fails to yield a diagnosis, patient-parent trio whole exome sequencing is recommended. The parental




Figure 4 Algorithm for the molecular diagnosis of CdLS.

specimens are then used to filter the variants identified in the index case (Fig. 4).

However, despite the significant progress made to date, there is still a considerable number of individuals in which genetic diagnosis is not achieved, which suggests the existence of causative genes and mechanisms of mutation that have yet to be identified.

Genotype-phenotype association

Although most individuals with classic CdLS have a pathogenic variant in gene *NIPBL* associated with the characteristic facial morphology and, in some cases, reduction deformities in the extremities, there are also patients with non-classic phenotypes (Fig. 5). The pathogenic variants of *NIPBL* are uniformly distributed through the coding region, but missense variants are more frequent in the HEAT repeat domain and are associated with a milder presentation.^{32,33}

Individual with pathogenic variants of the *SMC1A* or *SMC3* genes exhibit fewer structural anomalies and less severe growth retardation compared to individuals with pathogenic variants in *NIPBL*; however, they have significant intellectual disability that is moderate to severe.³⁵ Patients with pathogenic variants in the *SMC1A* present with slightly flatter and wider eyebrows and a long and wide nasal ridge, in some cases, they develop refractory epilepsy with an early onset.³⁶ Patients with pathogenic variants in the *SMC3* gene often present with subtle or no synophrys, and 56% have heart defects.³⁷




Figure 5 Cornelia de Lange spectrum. Cornelia de Lange syndrome can be considered an umbrella term comprehending a broad phenotypic spectrum. The diagram shows the clinical spectrum caused by changes in the *NIPBL*, *SMC1A*, *SMC3*, *HDAC8*, *RAD21* and other genes by means of arrows.

Individuals with a heterozygous pathogenic variant of *RAD21* usually have no major structural anomalies, and tend to present milder cognitive impairment and GER, with the latter limited to early childhood.³⁸ They usually exhibit growth delay, minor skeletal deformities and facial features that overlap with those of CdLS.

Male patients with hemizygous pathogenic variants in the *HDAC8* gene have the characteristic facial features of CdLS accompanied by delayed anterior fontanelle closure, hooding of the eyelids, orbital hypertelorism, pigmentary mosaicism, dental anomalies and, most saliently, a broad/bulbous nasal tip and a friendly personality. Growth delay is not as significant, with a lower frequency of postnatal growth retardation and microcephaly. Some of these patients may also exhibit severe reduction deformities in the extremities. In female patients, the presentation tends to be milder, but the severity is strongly associated with the X chromosome inactivation pattern.³⁹

Genetic counselling

Most CdLS cases are sporadic, especially in cases involving genes with autosomal dominant inheritance: *NIPBL*, *SMC3* and *RAD21*. In the case of pathogenic variants in X-linked genes (*SMC1A* and *HDAC8*), male patients tend to have more severe presentations compared to female patients. In these families, there are cases of parents with mild disease and the risk of transmission depends on the sex of the affected parent.³

More than 99% of patients with classic CdLS have a de novo heterozygous pathogenic variant in the *NIPBL* gene. This means that the risk of recurrence in future siblings is very low (1–2%) and chiefly due to the possibility of germline mosaicism in one of the parents.⁴⁰ In families in which a pathogenic variant has been identified in any of the genes associated with CdLS, prenatal genetic screening could be performed to detect or rule out the presence of the variant in the foetus.

Treatment and follow-up

At present, there is no curative treatment for CdLS, but there are symptomatic and palliative treatments that the paediatrician must be aware of. The main medical complication in classic CdLS (associated with the *NIPBL* gene) is GER, which is present in most patients and must be treated early and aggressively conforming to the validated treatment protocols in the paediatric literature. In some instances, when the patient does not respond well to the standard of care, alternative measures need to be used, such as nasogastric or gastrostomy tube feeding in the first months or years of life. Some patients ultimately require surgical treatment (Nissen fundoplication). When it comes to the digestive system, it is important to keep in mind the possible presence of intestinal malrotation that could become complicated, manifesting with constant or recurrent acute abdominal pain (due to obstruction or volvulus), bringing the patient to the emergency department (usually within 2 years from birth) where, if the cause is not identified early, the outcome could be death.³

Hearing should be tested from birth (otoacoustic emission test); in the case of negative or uncertain results, auditory evoked potential testing should be performed so that, should sensorineural hearing loss be detected, hearing aid devices (audiphone or cochlear implant) can be placed as soon as possible, preferably before the age when speech starts to develop. The evaluation should also include an echocardiogram and an abdominal ultrasound examination to assess for the presence of structural anomalies in the heart and the organs in the abdominal cavity (kidneys).

As regards psychomotor development, most patients with CdLS require intervention to stimulate language development (speech-language therapy) and motor development (physical and/or occupational therapy). Some patients may need pharmacotherapy to manage hyperactivity and/or attention deficit.

In November 2023, the XII CdLS World Conference was held in Zaragoza by the Reference Centre for CdLS in collaboration with the Asociación Española del Síndrome de Cornelia de Lange (Spanish Association of CdLS) and the CdLS World Federation. The congress gathered the main experts worldwide, who shared the latest advances in the knowledge of the syndrome. In the clinical area, we ought to highlight the novel technique of sensory neuromodulation to treat refractory epilepsy in patients with CdLS and pathogenic variants of the *SMC1A* gene, which has proven effective in 3 out of 4 treated patients. The importance of contemplating the possibility of intestinal malrotation in any child with CdLS presenting to the emergency department with acute abdominal pain was also addressed. In respect of anaesthetic procedures in children with CdLS, presenters insisted that experience has demonstrated that they are well tolerated by patients. In the basic research section, evidence was presented confirming that the absence of cohesin gives rise to changes in DNA transcription, in addition to novel 3D models of cohesin that could help identify potential therapeutic targets in CdLS. Animal models are also being developed to start clinical trials of Ataluren for treatment of epilepsy in patients with CdLS-SMC1A. Results from single-cell sequencing studies were presented that evinced the presence of transcriptional dysregulation in the early stages of embry-

onal development in a mouse model. The first findings on the subject of cellular senescence in CdLS, obtained with pluripotent stem cells derived from patients with CdLS, were also presented.

Funding

Strategic Health Action programme (*Acción Estratégica en Salud* [AES], Instituto de Salud Carlos III, Ministry of Science, Innovation and Universities of Spain): Project PI23/01370; Government of Aragón (Diputación General): Research Group B32-20R.

Conflicts of interest

The authors have no conflicts of interest to declare.

References

1. De Lange C. Sur un type nouveau de dégénération (typus Amstelodamensis) [On a new type of degeneration (type Amsterdam)]. *Arch Med Enfants*. 1933;36.
2. Brachmann W. Ein Fall von symmetrischer Monodaktylie durch Ulnadefekt, mit symmetrischer Flughautbildung in den Ellenbogen, sowie anderen Abnormalitäten (Zwerghaftigkeit, Halsrippen, Behaarung). *Jahrbuch Kinderheilkd phys Erzieh*. 1916;84:225.
3. Kline AD, Moss JF, Selicorni A, Bisgaard AM, Deardorff MA, Gillett PM, et al. Diagnosis and management of Cornelia de Lange syndrome: first international consensus statement. *Nat Rev Genet*. 2018;19:649–66.
4. Kline AD, Krantz ID, Sommer A, Kliewer M, Jackson LG, FitzPatrick DR, et al. Cornelia de Lange syndrome: clinical review, diagnostic and scoring systems, and anticipatory guidance. *Am J Med Genet A*. 2007;12:1287–96.
5. Bruner JP, Hsia YE. Prenatal finding in Brachmann-de Lange syndrome. *Obstet Gynecol*. 1990;76:966–8.
6. Kline AD, Barr M, Jackson LG. Growth manifestations in the Brachmann-de Lange syndrome. *Am J Med Genet*. 1993;47:1042–9.
7. Kline AD, Stanley C, Belevich J, Brodsky K, Barr M, Jackson LG. Developmental data on individuals with the Brachmann-de Lange syndrome. *Am J Med Genet*. 1993;47:1053–8.
8. de Graaf M, Kant SG, Wit JM, Willem Redeker EJ, Eduard Santen GW, Henriëtta Verkerk AJM, et al. Successful growth hormone therapy in Cornelia de Lange syndrome. *J Clin Res Pediatr Endocrinol*. 2017;9:366–70.
9. Ascaso Á, Latorre-Pellicer A, Puisac B, Trujillano L, Arnedo M, Parenti I, et al. Endocrine evaluation and homeostatic model assessment in patients with Cornelia de Lange syndrome. *J Clin Res Pediatr Endocrinol*. 2022, <http://dx.doi.org/10.4274/jcrpe.galenos.2022.2022-4-14>.
10. Moss J, Oliver C, Arron K, Burbidge C, Berg K. The prevalence and phenomenology of repetitive behavior in genetic syndromes. *J Autism Dev Disord*. 2009;39:572–88.
11. Pablo MJ, Pamplona P, Haddad M, Benavente I, Latorre-Pellicer A, Arnedo M, et al. High rate of autonomic neuropathy in Cornelia de Lange syndrome. *Orphanet J Rare Dis*. 2021;16:458.
12. Mehta D, Vergano SA, Deardorff M, Aggarwal S, Barot A, Johnson DM, et al. Characterization of limb differences in children with Cornelia de Lange syndrome. *Am J Med Genet C Semin Med Genet*. 2016;172:155–62.
13. Luzzani S, Macchini F, Valadè A, Milani D, Selicorni A. Gastroesophageal reflux and Cornelia de Lange syndrome: typical and atypical symptoms. *Am J Med Genet A*. 2003;119:283–7.
14. Kline AD, Grados M, Sponseller P, Levy HP, Blagowidow N, Schoedel C, et al. Natural history of aging in Cornelia de Lange syndrome. *Am J Med Genet C Semin Med Genet*. 2007;145:248–60.
15. Marino T, Wheeler PG, Simpson LL, Craig SD, Bianchi DW. Fetal diaphragmatic hernia and upper limb anomalies suggest Brachmann-de Lange syndrome. *Prenat Diagn*. 2002;22:144–7.
16. Sataloff RT, Spiegel JR, Hawkshaw M, Epstein JM, Jackson L. Cornelia de Lange syndrome. Otolaryngologic manifestations. *Arch Otolaryngol Head Neck Surg*. 1990;116:1044–6.
17. Nallasamy S, Kherani F, Yaeger D, McCallum J, Kaur M, Devoto M, et al. Ophthalmologic findings in Cornelia de Lange syndrome: a genotype-phenotype correlation study. *Arch Ophthalmol*. 2006;124:552–7.
18. Ayerza Casas A, Puisac Uriol B, Teresa Rodrigo ME, Hernández Marcos M, Ramos Fuentes FJ, Pie Juste J. Cornelia de Lange syndrome: congenital heart disease in 149 patients. *Med Clin (Barc)*. 2017;149:300–2.
19. Trujillano L, Ayerza-Casas A, Puisac B, García GG, Ascaso Á, Latorre-Pellicer A, et al. Subclinical myocardial dysfunction is revealed by speckle tracking echocardiography in patients with Cornelia de Lange syndrome. *Int J Cardiovasc Imaging*. 2022;38:2291–302.
20. Oliver C, Bedeschi MF, Blagowidow N, Carrico CS, Cereda A, Fitzpatrick DR, et al. Cornelia de Lange syndrome: extending the physical and psychological phenotype. *Am J Med Genet A*. 2010;152:1127–35.
21. Matute-Llorente Á, Ascaso Á, Latorre-Pellicer A, Puisac B, Trujillano L, Llorente E, et al. Targeted gene sequencing, bone health, and body composition in Cornelia de Lange syndrome. *Appl Sci*. 2021;11:710.
22. Santen GW, Aten E, Vulto-van Silfhout AT, Pottinger C, van Bon BW, van Minderhout IJ, et al. Coffin-Siris syndrome and the BAF complex: genotype-phenotype study in 63 patients. *Hum Mutat*. 2013;34:1519–28.
23. Fergelot P, Van Belzen M, Van Gils J, Afenjar A, Armour CM, Arveiler B, et al. Phenotype and genotype in 52 patients with Rubinstein-Taybi syndrome caused by EP300 mutations. *Am J Med Genet A*. 2016;170:3069–82.
24. Parenti I, Mallozzi MB, Hüning I, Gervasini C, Kuechler A, Agolini E, et al. ANKRD11 variants: KBG syndrome and beyond. *Clin Genet*. 2021;100:187–200.
25. Izumi K, Nakato R, Zhang Z, Edmondson AC, Noon S, Dulik MC, et al. Germline gain-of-function mutations in AFF4 cause a developmental syndrome functionally linking the super elongation complex and cohesin. *Nat Genet*. 2015;47:338–44.
26. Castiglioni S, Di Fede E, Bernardelli C, Lettieri A, Parodi C, Grazioli P, et al. KMT2A: umbrella gene for multiple diseases. *Genes (Basel)*. 2022;13:514.
27. Latorre-Pellicer A, Ascaso Á, Trujillano L, Gil-Salvador M, Arnedo M, Lucia-Campos C, et al. Evaluating Face2Gene as a tool to identify Cornelia de Lange syndrome by facial phenotypes. *Int J Mol Sci*. 2020;21:1042.
28. Kaur M, Blair J, Devkota B, Fortunato S, Clark D, Lawrence A, et al. Genomic analyses in Cornelia de Lange syndrome and related diagnoses: novel candidate genes, genotype-phenotype correlations and common mechanisms. *Am J Med Genet A*. 2023;191:2113–31. Epubaheadofprint.-L.
29. Parenti I, Diab F, Gil SR, Mulugeta E, Casa V, Berutti R, et al. MAU2 and NIPBL variants impair the heterodimerization of the cohesin loader subunits and cause Cornelia de Lange syndrome. *Cell Rep*. 2020;31:107647.
30. Alonso-Gil D, Losada A. NIPBL and cohesin: new take on a classic tale. *Trends Cell Biol*. 2023;33:860–71.

31. Olley G, Ansari M, Bengani H, Grimes GR, Rhodes J, von Kriegsheim A, et al. BRD4 interacts with NIPBL and BRD4 is mutated in a Cornelia de Lange-like syndrome. *Nat Genet.* 2018;50:329–32.
32. Latorre-Pellicer A, Gil-Salvador M, Parenti I, Lucia-Campos C, Trujillano L, Marcos-Alcalde I, et al. Clinical relevance of postzygotic mosaicism in Cornelia de Lange syndrome and purifying selection of NIPBL variants in blood. *Sci Rep.* 2021;11:15459.
33. Gil-Salvador M, Latorre-Pellicer A, Lucia-Campos C, Arnedo M, Darnaude MT, Diaz de Bustamante A, et al. Case report: a novel case of parental mosaicism in SMC1A gene causes inherited Cornelia de Lange syndrome. *Front Genet.* 2022;13:993064.
34. Pié J, Gil-Rodríguez MC, Ciero M, López-Viñas E, Ribate MP, Arnedo M, et al. Mutations and variants in the cohesion factor genes NIPBL, SMC1A, and SMC3 in a cohort of 30 unrelated patients with Cornelia de Lange syndrome. *Am J Med Genet A.* 2010;152:924–9.
35. Deardorff MA, Kaur M, Yaeger D, Rampuria A, Korolev S, Pie J, et al. Mutations in cohesin complex members SMC3 and SMC1A cause a mild variant of cornelia de Lange syndrome with predominant mental retardation. *Am J Hum Genet.* 2007;80:485–94.
36. Bozarth XL, Lopez J, Fang H, Lee-Eng J, Duan Z, Deng X. Phenotypes and genotypes in patients with SMC1A-related developmental and epileptic encephalopathy. *Genes (Basel).* 2023;14:852.
37. Gil-Rodríguez MC, Deardorff MA, Ansari M, Tan CA, Parenti I, Baquero-Montoya C, et al. De novo heterozygous mutations in SMC3 cause a range of Cornelia de Lange syndrome-overlapping phenotypes. *Hum Mutat.* 2015;36:454–62.
38. Krab LC, Marcos-Alcalde I, Assaf M, Balasubramanian M, Andersen JB, Bisgaard AM, et al. Delineation of phenotypes and genotypes related to cohesin structural protein RAD21. *Hum Genet.* 2020;139:575–92.
39. Kaiser FJ, Ansari M, Braunholz D, Gil-Rodriguez MC, Decroos C, Wilde JJ, et al. Loss-of-function HDAC8 mutations cause a phenotypic spectrum of Cornelia de Lange syndrome-like features, ocular hypertelorism, large fontanelle and X-linked inheritance. *Hum Mol Genet.* 2014;23:2888–900.
40. Slavin TP, Lazebnik N, Clark DM, Vengoechea J, Cohen L, Kaur M, et al. Germline mosaicism in Cornelia de Lange syndrome. *Am J Med Genet A.* 2012;158:1481–5.